Grazax

Grazax is a sublingual tablet that contains 225 µg of the grass pollen allergen Phleum pratense. It is marketed in the European Union as an allergen immunotherapy product designed to modify the immune response to grass pollen exposure. The tablet is taken orally under the tongue and is intended for use in individuals with confirmed grass pollen allergy, following medical evaluation.

Grazax is indicated for the treatment of allergic rhinitis caused by grass pollen. Clinical use focuses on long‑term reduction of symptoms and medication need.

- Reduces seasonal nasal congestion, sneezing, and itchy eyes associated with grass pollen. - Decreases reliance on antihistamines and nasal corticosteroids during grass season. - Suitable for adults and children with a confirmed grass pollen allergy. - Administered daily throughout the grass pollen season to maintain tolerance. - May be considered as part of a broader allergy management plan.

Side effects of Grazax vary in frequency and severity. Most users experience mild, transient reactions, while rare serious events require medical attention.

Common: - Oral itching or mild throat irritation. - Ear or nasal itching. - Mild gastrointestinal discomfort. - Transient swelling of the lips or tongue. - Localized rash at the site of tablet placement.

Serious: - Anaphylaxis or severe systemic allergic reaction. - Persistent swelling of the throat that interferes with breathing. - Severe urticaria (hives) covering large body areas. - Acute bronchospasm or wheezing. - Rapid onset of cardiovascular symptoms such as hypotension.

Before starting Grazax, certain precautions should be considered to ensure safe use.

- Confirm diagnosis of grass pollen allergy through skin testing or specific IgE measurement. - Avoid use in individuals with uncontrolled asthma or recent asthma exacerbations. - Do not initiate therapy in patients who have experienced anaphylaxis to grass pollen extracts. - Monitor for local oral reactions during the first weeks of treatment. - Discuss any history of cardiovascular disease with a healthcare professional. - Pregnant or breastfeeding individuals should consult a physician before use.

Grazax may interact with other medications or substances that affect the immune system or allergic response.

Avoid: - Concurrent use of other sublingual or subcutaneous grass pollen immunotherapy products. - Administration of systemic antihistamines or corticosteroids immediately before the tablet, as they may mask early reactions.

Use with caution: - Beta‑blockers, which can interfere with treatment of anaphylaxis. - ACE inhibitors, due to potential for increased angioedema risk. - Immunosuppressive agents that may alter the intended immune response. - Herbal supplements that have known allergenic potential.